Fundraising Fox
Kalvista
257 employees · 3 known investors
Find your way into Kalvista
Sign up to see every warm intro you have to Kalvista
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kalvista team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE). Its pipeline includes preclinical oral Factor XIIa inhibitors targeting HAE prophylaxis as well as thrombosis and inflammation.
Investors · 3
Frequently asked questions
- What does Kalvista do?
- KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE). Its pipeline includes preclinical oral Factor XIIa inhibitors targeting HAE prophylaxis as well as thrombosis and inflammation.
- Who are Kalvista's investors?
- Kalvista's investors include Frazier Life Sciences, Longwood Fund, RA Capital.